PEOPLE ON THE MOVE
PlaqueTec
Cambridge, UK-based company PlaqueTec has made Tim Brears CEO.
The firm uses biomarkers to research coronary artery disease (CAD) and develop new cardiovascular drugs for target populations.
Brears was until recently CEO of Xention Limited, a company he founded for the development of drugs to control of atrial fibrillation. Previously, he was chief executive of Gendaq Limited, a gene-regulation company later acquired by Sangamo Biosciences. From 1993 to 1999 he was director of licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.
